1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Ohio >
  6. Amicus Therapeutics Acquires Celenex

M&A Deal Summary

Amicus Therapeutics Acquires Celenex

On September 20, 2018, Amicus Therapeutics acquired life science company Celenex for 175M USD

Acquisition Highlights
  • This is Amicus Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Amicus Therapeutics’ 2nd largest (disclosed) transaction.
  • This is Amicus Therapeutics’ 2nd transaction in the United States.
  • This is Amicus Therapeutics’ 1st transaction in Ohio.

M&A Deal Summary
Date 2018-09-20
Target Celenex
Sector Life Science
Buyer(s) Amicus Therapeutics
Deal Type Add-on Acquisition
Deal Value 175M USD
Advisor(s) RBC Capital Markets (Financial)
Fenwick & West (Legal)

Target

Celenex

Columbus, Ohio, United States
Celenex is a clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. Celenex is based in Columbus, Ohio.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Amicus Therapeutics

Princeton, New Jersey, United States
Category Company
Founded 2002
Sector Life Science
Revenue 528M USD (2024)
DESCRIPTION

Amicus Therapeutics is a biotechnology company at the forefront of therapies for rare and orphan diseases. Amicus Therapeutics was founded in 2002 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: Ohio M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2018 M&A 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-30 Scioderm

Raleigh, North Carolina, United States

Scioderm, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address diseases with high unmet need, including rare diseases.

Buy $229M
Mergr

Solution for

Product

Company

Legal